Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jupiter Neurosciences, Inc. (NASDAQ: JUNS) SEC filings page on Stock Titan provides structured access to the company’s official regulatory disclosures as a clinical-stage pharmaceutical and consumer health business. Jupiter focuses on neuroinflammation, CNS disorders, rare diseases, and healthy aging through its JOTROL™ resveratrol platform and Nugevia™ longevity supplements, and its filings offer detailed insight into how these activities are financed, governed, and reported.
Here, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Jupiter’s therapeutic pipeline, the status of its Phase IIa Parkinson’s disease program, the Nugevia™ product line, risk factors, and accounting policies. Notifications such as Form 12b-25 (NT 10-Q) explain any delays in periodic reporting and provide context on financial statement preparation.
Current reports on Form 8-K document material events, including the Standby Equity Purchase Agreement and related convertible notes with an affiliate of Yorkville Advisors, Nasdaq bid-price compliance updates, and other significant corporate actions. Definitive proxy statements on Schedule 14A outline proposals for stockholders, such as increases in authorized common stock, equity incentive plans, auditor ratification, and approvals related to potential share issuances under financing agreements.
Stock Titan enhances these documents with AI-powered summaries that highlight key terms, capital structure implications, and governance decisions, helping users quickly understand long, technical filings. Investors can also monitor registration-related documents and any insider or equity-linked disclosures that appear in the EDGAR record. With real-time updates from the SEC and machine-generated overviews, this page is designed to make Jupiter Neurosciences’ regulatory history and ongoing reporting easier to navigate for JUNS shareholders and researchers.
Jupiter Neurosciences, Inc. filed a notice that it will be late in submitting its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The company states it could not complete the filing on time without unreasonable effort or expense.
Management explains that it needs additional time to finish preparing and reviewing its financial statements and related disclosures. The company expects to file the Form 10-Q no later than the fifth calendar day after the original due date, consistent with the extension allowed under Rule 12b-25.
Jupiter Neurosciences (JUNS) Form 4 filing: President, Chief Business Officer and Director Alison D. Silva reported three open-market purchases on 01 July 2025 totaling 750 common shares at an average price of roughly $1.03 per share. Following the transactions, Silva directly owns 112,777 shares of JUNS common stock. No derivative security activity was disclosed.
The transactions are coded “P,” indicating routine open-market buys and not part of a Rule 10b5-1 trading plan. While the dollar value is modest (≈ $770), insider buying is generally interpreted as a vote of confidence in the company’s prospects. However, the size of the purchase is immaterial to overall share count and does not meaningfully affect ownership structure.